Collaborative Arrangements and Licensing Agreements (Tables)

6 Months Ended

Jun. 30, 2025

AstraZeneca [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Agreement

During the three and six months ended June 30, 2025 and 2024, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentage amounts):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
		2025			2024			2025			2024
Revenue from our relationship with AstraZeneca	$	54,288		$	15,960		$	74,577		$	27,645
Percentage of total revenue		12	%		7	%		13	%		8	%

Ono [Member]

Collaborative Arrangements and Licensing Agreements [Abstract]

Revenue from Collaborative Agreement

During the three and six months ended June 30, 2025 and 2024, we earned the following revenue from our relationship with Ono (in thousands, except percentage amounts):

		Three Months Ended			Six Months Ended
		June 30, 2025			June 30, 2025
Revenue from our relationship with Ono	$	280,000		$	280,000
Percentage of total revenue		62	%		48	%